Active substance
Sulpiride
- SFDA 6
- NHS prices 3
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DOGMATIL AMP 100MG | 100 mg | Solution for injection · Intravenous use | 6 Ampoule | SAR 10.80 | NCE · Prescription | sanofi-aventis | Valid |
| DOGMATIL CAPS 50MG | 50 mg | Capsule, hard · Oral use | 30 Blister | SAR 21.40 | NCE · Prescription | sanofi-aventis | Valid |
| DOGMATIL FORT TAB 200MG | 200 mg | Scored tablet · Oral use | 12 Blister | SAR 22.50 | NCE · Prescription | sanofi-aventis | Valid |
| GENPRID | 200 mg | Tablet · Oral use | 20 Blister | SAR 27.80 | Generic · Prescription | EVA PHARMA | Valid |
| GENPRID | 50 mg | Capsule · Oral use | 30 Blister | SAR 12.40 | Generic · Prescription | EVA PHARMA | Valid |
| DOGMATIL SYP | 5 mg/ml | Syrup · Oral use | 1 Bottle | SAR 10.25 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
TOURETTE SYNDROME
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Sulpiride 200mg tablets | £4.96 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Sulpiride 200mg/5ml oral solution sugar free | £101.13 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Sulpiride 400mg tablets | £19.37 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.